

Key data to be presented at EAHAD 2025

ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study	Oral presentation. #OR12 Session date: Friday, 07 February 2025 Presentation time: 13:45-15:15
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program	Oral presentation. #OR02 Session date: Friday, 07 February 2025 Presentation time: 08:30 - 10:00
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed	Poster presentation. #PO109 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Clinical outcomes over 2 years of efanesoctocog alfa in children with severe haemophilia A: European results from the second interim analysis of XTEND-ed	Poster presentation. # PO148 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults and Adolescents with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Long-term Extension Study	Poster presentation. #PO060 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi.	Patient characteristics in FREEDOM, a study evaluating physical activity and joint health in patients with haemophilia A receiving efanesoctocog alfa prophylaxis	Poster presentation. #PO047 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa)	Assessment of treatment schedule, factor VIII trough level, and area under the curve for efanesoctocog alfa vs an extended half-life FVIII comparator: a modelling approach	Poster presentation. #PO115 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
ALTUVOCT (efanesoctocog alfa)	Impact of a hypothetical switch to efanesoctocog alfa prophylaxis on bleeding, treatment burden and area under the curve in severe haemophilia A: Italian CHES III cohort analysis	Poster presentation. #PO127 Session date: Welcome Reception, Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
Elocta®/Eloctate® (efmoroctocog alfa)	Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study	Poster presentation. #PO120 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30
Elocta®/Eloctate® (efmoroctocog alfa)	Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study	Poster presentation. #PO079 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30